|
Event
|
During ACCORD-lipid (short-term effect)
|
P
|
Post-trial only (legacy effect)
|
P
|
Full follow-up (long-term effect)
|
P
|
|---|
|
Rate of events (100 person-years)
|
Hazard Ratio (95% CI)
|
Rate of events (100 person-years)
|
Hazard ratio (95% CI)
|
Rate of events (100 person-years)
|
Hazard ratio (95% CI)
|
|---|
|
Fibrate
|
Placebo
|
Fibrate
|
Placebo
|
Fibrate
|
Placebo
|
|---|
|
All-cause mortality
|
1.54
|
2.26
|
0.68 (0.44, 1.04)
|
0.07
|
3.05
|
4.43
|
0.65 (0.45, 0.94)
|
0.02
|
2.23
|
3.24
|
0.68 (0.52, 0.88)
|
< 0.01
|
|
CVD mortality
|
0.67
|
1.28
|
0.53 (0.29, 0.98)
|
0.04
|
1.12
|
1.53
|
0.77 (0.43, 1.39)
|
0.38
|
0.88
|
1.39
|
0.63 (0.42, 0.95)
|
0.03
|
|
Nonfatal MI
|
1.76
|
2.45
|
0.72 (0.47, 1.09)
|
0.12
|
0.85
|
1.07
|
0.74 (0.33, 1.66)
|
0.47
|
1.40
|
1.91
|
0.74 (0.51, 1.06)
|
0.10
|
|
Stroke
|
0.56
|
0.74
|
0.75 (0.36, 1.56)
|
0.44
|
0.56
|
0.55
|
0.87 (0.33, 2.29)
|
0.78
|
0.58
|
0.67
|
0.88 (0.5, 1.56)
|
0.66
|
|
CHF
|
1.39
|
1.51
|
0.90 (0.55, 1.47)
|
0.68
|
0.65
|
0.93
|
0.69 (0.30, 1.57)
|
0.38
|
1.07
|
1.27
|
0.82 (0.54, 1.24)
|
0.35
|
|
Major CHD
|
3.01
|
4.60
|
0.65 (0.48, 0.90)
|
0.01
|
2.17
|
3.27
|
0.64 (0.40, 1.03)
|
0.07
|
2.67
|
4.09
|
0.66 (0.51, 0.86)
|
< 0.01
|
- MI myocardial infarction, CHF congestive heart failure, CHD coronary heart disease
